Fibrinogen-related proteins (FRePs) comprise an intriguing collection of extracellular molecules, each containing a conserved fibrinogen-like globe (FBG). This group includes the eponymous fibrinogen as well as the tenascin, angiopoietin, and ficolin families. Many of these proteins are upregulated during tissue repair and exhibit diverse roles during wound healing.
Recent Advances:
An increasing body of evidence highlights the specific expression of a number of FRePs following tissue injury and infection. Upon induction, each FReP uses its FBG domain to mediate quite distinct effects that contribute to different stages of tissue repair, such as driving coagulation, pathogen detection, inflammation, angiogenesis, and tissue remodeling.
Critical Issues:
Despite a high degree of homology among FRePs, each contains unique sequences that enable their diversification of function. Comparative analysis of the structure and function of FRePs and precise mapping of regions that interact with a variety of ligands has started to reveal the underlying molecular mechanisms by which these proteins play very different roles using their common domain.
Future Directions:
Fibrinogen has long been used in the clinic as a synthetic matrix serving as a scaffold or a delivery system to aid tissue repair. Novel therapeutic strategies are now emerging that harness the use of other FRePs to improve wound healing outcomes. As we learn more about the underlying mechanisms by which each FReP contributes to the repair response, specific blockade, or indeed potentiation, of their function offers real potential to enable regulation of distinct processes during pathological wound healing.
Get full access to this article
View all access options for this article.
References
1.
YeeVC, et al.Crystal structure of a 30 kDa C-terminal fragment from the gamma chain of human fibrinogen. Structure, 1997; 5:125–138.
2.
DoolittleRF. A detailed consideration of a principal domain of vertebrate fibrinogen and its relatives. Protein Sci, 1992; 1:1563–1577.
3.
DoolittleRF, McNamaraK, LinK. Correlating structure and function during the evolution of fibrinogen-related domains. Protein Sci, 2012; 21:1808–1823.
4.
HaningtonPC, ZhangSM. The primary role of fibrinogen-related proteins in invertebrates is defense, not coagulation. J Innate Immun, 2011; 3:17–27.
5.
KingN, et al.The genome of the choanoflagellate Monosiga brevicollis and the origin of metazoans. Nature, 2008; 451:783–788.
6.
GarlattiV, et al.Structural insights into the innate immune recognition specificities of L- and H-ficolins. EMBO J, 2007; 26:623–633.
7.
GarlattiV, et al.Structural basis for innate immune sensing by M-ficolin and its control by a pH-dependent conformational switch. J Biol Chem, 2007; 282:35814–35820.
8.
BartonWA, TzvetkovaD, NikolovDB. Structure of the angiopoietin-2 receptor binding domain and identification of surfaces involved in Tie2 recognition. Structure, 2005; 13:825–832.
9.
ShriveAK, et al.Crystal structure of the tetrameric fibrinogen-like recognition domain of fibrinogen C domain containing 1 (FIBCD1) protein. J Biol Chem, 2014; 289:2880–2887.
10.
KairiesN, et al.The 2.0-A crystal structure of tachylectin 5A provides evidence for the common origin of the innate immunity and the blood coagulation systems. Proc Natl Acad Sci U S A, 2001; 98:13519–13524.
11.
SwindleCS, et al.Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol, 2001; 154:459–468.
12.
RodriguesM, et al.The matrikine tenascin-C protects multipotential stromal cells/mesenchymal stem cells from death cytokines such as FasL. Tissue Eng Part A, 2013; 19:1972–1983.
13.
ChanCW, et al.Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J Immunol, 2002; 168:5170–5177.
14.
PrattKP, et al.The primary fibrin polymerization pocket: three-dimensional structure of a 30-kDa C-terminal gamma chain fragment complexed with the peptide Gly-Pro-Arg-Pro. Proc Natl Acad Sci U S A, 1997; 94:7176–7181.
15.
LitvinovRI, et al.Polymerization of fibrin: specificity, strength, and stability of knob-hole interactions studied at the single-molecule level. Blood, 2005; 106:2944–2951.
16.
EverseSJ, et al.Crystal structure of fragment double-D from human fibrin with two different bound ligands. Biochemistry, 1998; 37:8637–8642.
17.
OkumuraN, GorkunOV, LordST. Severely impaired polymerization of recombinant fibrinogen gamma-364 Asp—>His, the substitution discovered in a heterozygous individual. J Biol Chem, 1997; 272:29596–29601.
18.
WeiselJW, LitvinovRI. Mechanisms of fibrin polymerization and clinical implications. Blood, 2013; 121:1712–1719.
19.
ChenR, DoolittleRF. Cross-linking sites in human and bovine fibrin. Biochemistry, 1971; 10:4487–4491.
20.
FarrellDH, ThiagarajanP. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem, 1994; 269:226–231.
21.
PodolnikovaNP, et al.Identification of a novel binding site for platelet integrins alpha IIb beta 3 (GPIIbIIIa) and alpha 5 beta 1 in the gamma C-domain of fibrinogen. J Biol Chem, 2003; 278:32251–32258.
22.
FornaceAJJr., et al.Structure of the human gamma-fibrinogen gene. Alternate mRNA splicing near the 3′ end of the gene produces gamma A and gamma B forms of gamma-fibrinogen. J Biol Chem, 1984; 259:12826–12830.
23.
MehDA, et al.The amino acid sequence in fibrin responsible for high affinity thrombin binding. Thromb Haemost, 2001; 85:470–474.
24.
SiebenlistKR, MehDA, MosessonMW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry, 1996; 35:10448–10453.
25.
FarrellDH, et al.Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci U S A, 1992; 89:10729–10732.
ColletJP, et al.Influence of gamma’ fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol, 2004; 24:382–386.
28.
LovelyRS, et al.Assessment of genetic determinants of the association of gamma’ fibrinogen in relation to cardiovascular disease. Arterioscler Thromb Vasc Biol, 2011; 31:2345–2352.
29.
CheungEY, et al.Specific effects of fibrinogen and the gammaA and gamma’-chain fibrinogen variants on angiogenesis and wound healing. Tissue Eng Part A, 2014 [Epub ahead of print]; DOI: 10.1089/ten.tea.2014.0020.
30.
RenY, DingQ, ZhangX. Ficolins and infectious diseases. Virol Sin, 2014; 29:25–32.
31.
LeY, et al.Human L-ficolin: plasma levels, sugar specificity, and assignment of its lectin activity to the fibrinogen-like (FBG) domain. FEBS Lett, 1998; 425:367–370.
32.
LynchNJ, et al.L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J Immunol, 2004; 172:1198–1202.
33.
KilpatrickDC, et al.Stable bronchiectasis is associated with low serum L-ficolin concentrations. Clin Respir J, 2009; 3:29–33.
34.
AoyagiY, et al.Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci. J Immunol, 2005; 174:418–425.
35.
FrederiksenPD, et al.M-ficolin, an innate immune defence molecule, binds patterns of acetyl groups and activates complement. Scand J Immunol, 2005; 62:462–473.
36.
TehC, et al.M-ficolin is expressed on monocytes and is a lectin binding to N-acetyl-D-glucosamine and mediates monocyte adhesion and phagocytosis of Escherichia coli. Immunology, 2000; 101:225–232.
37.
LuoF, et al.Ficolin-2 defends against virulent Mycobacteria tuberculosis infection in vivo, and its insufficiency is associated with infection in humans. PLoS One, 2013; 8:e73859.
38.
HuYL, et al.Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand J Immunol, 2013; 77:144–150.
39.
PanQ, et al.L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun, 2012; 4:312–324.
40.
JensenML, et al.Ficolin-2 recognizes DNA and participates in the clearance of dying host cells. Mol Immunol, 2007; 44:856–865.
41.
AmmitzbollCG, et al.Non-synonymous polymorphisms in the FCN1 gene determine ligand-binding ability and serum levels of M-ficolin. PLoS One, 2012; 7:e50585.
42.
TsujimuraM, et al.Detection of serum thermolabile beta-2 macroglycoprotein (Hakata antigen) by enzyme-linked immunosorbent assay using polysaccharide produced by Aerococcus viridans. Clin Diagn Lab Immunol, 2001; 8:454–459.
43.
VermaA, et al.Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses. J Immunol, 2012; 189:2478–2487.
44.
SwierzkoA, et al.New functional ligands for ficolin-3 among lipopolysaccharides of Hafnia alvei. Glycobiology, 2012; 22:267–280.
45.
MichalskiM, et al.Ficolin-3 activity towards the opportunistic pathogen, Hafnia alvei. Immunobiology, 2014. DOI: 10.1016/j.imbio.2014.08.012.
46.
HonoreC, et al.The innate immune component ficolin 3 (Hakata antigen) mediates the clearance of late apoptotic cells. Arthritis Rheum, 2007; 56:1598–1607.
47.
Munthe-FogL, et al.Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med, 2009; 360:2637–2644.
48.
SchlosserA, et al.Characterization of FIBCD1 as an acetyl group-binding receptor that binds chitin. J Immunol, 2009; 183:3800–3809.
49.
ThomsenT, et al.The recognition unit of FIBCD1 organizes into a noncovalently linked tetrameric structure and uses a hydrophobic funnel (S1) for acetyl group recognition. J Biol Chem, 2010; 285:1229–1238.
50.
YuwarajS, et al.Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: a novel human procoagulant. Genomics, 2001; 71:330–338.
51.
LiuY, et al.The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway. Biochem Biophys Res Commun, 2010; 396:555–561.
52.
FoersterK, et al.The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. J Hepatol, 2010; 53:608–615.
53.
JiaP, et al.TNF-alpha upregulates Fgl2 expression in rat myocardial ischemia/reperfusion injury. Microcirculation, 2013; 20:524–533.
54.
SelznerN, et al.FGL2/fibroleukin mediates hepatic reperfusion injury by induction of sinusoidal endothelial cell and hepatocyte apoptosis in mice. J Hepatol, 2012; 56:153–159.
55.
ChanCW, et al.Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J Immunol, 2003; 170:4036–4044.
56.
MidwoodK, et al.Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med, 2009; 15:774–780.
57.
LaurensN, KoolwijkP, de MaatMP. Fibrin structure and wound healing. J Thromb Haemost, 2006; 4:932–939.
YakovlevS, et al.Interaction of fibrin(ogen) with leukocyte receptor alpha M beta 2 (Mac-1): further characterization and identification of a novel binding region within the central domain of the fibrinogen gamma-module. Biochemistry, 2005; 44:617–626.
60.
FagianiE, ChristoforiG. Angiopoietins in angiogenesis. Cancer Lett, 2013; 328:18–26.
61.
KampferH, PfeilschifterJ, FrankS. Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab Invest, 2001; 81:361–373.
62.
FiedlerU, et al.The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood, 2004; 103:4150–4156.
63.
StatonCA, et al.Angiopoietin-1, angiopoietin-2 and Tie-2 receptor expression in human dermal wound repair and scarring. Br J Dermatol, 2010; 163:920–927.
64.
MaisonpierrePC, et al.Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 1997; 277:55–60.
65.
HarfoucheR, HussainSN. Signaling and regulation of endothelial cell survival by angiopoietin-2. Am J Physiol Heart Circ Physiol, 2006; 291:H1635–H1645.
66.
LeeHS, et al.Gln362 of angiopoietin-2 mediates migration of tumor and endothelial cells through association with alpha5beta1 integrin. J Biol Chem, 2014; 289:31330–31340.
67.
GaleNW, et al.Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell, 2002; 3:411–423.
68.
GoodsonWH3rd, HungTK. Studies of wound healing in experimental diabetes mellitus. J Surg Res, 1977; 22:221–227.
69.
BohlenHG, NigglBA. Adult microvascular disturbances as a result of juvenile onset diabetes in Db/Db mice. Blood Vessels, 1979; 16:269–276.
70.
ThurstonG, et al.Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science, 1999; 286:2511–2514.
71.
JeanssonM, et al.Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest, 2011; 121:2278–2289.
72.
CarlsonTR, et al.Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem, 2001; 276:26516–26525.
73.
BittoA, et al.Angiopoietin-1 gene transfer improves impaired wound healing in genetically diabetic mice without increasing VEGF expression. Clin Sci (Lond), 2008; 114:707–718.
74.
LiY, et al.Mesenchymal stem cells modified with angiopoietin-1 gene promote wound healing. Stem Cell Res Ther, 2013; 4:113.
75.
Van SlykeP, et al.Acceleration of diabetic wound healing by an angiopoietin peptide mimetic. Tissue Eng Part A, 2009; 15:1269–1280.
76.
KorpelaE, et al.Vasculotide, an Angiopoietin-1 mimetic, reduces acute skin ionizing radiation damage in a preclinical mouse model. BMC Cancer, 2014; 14: 614.
77.
HatoT, TabataM, OikeY. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med, 2008; 18:6–14.
78.
CamenischG, et al.ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem, 2002; 277:17281–17290.
79.
SahniA, et al.FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Blood, 2006; 107:126–131.
80.
YokoyamaK, et al.Identification of amino acid sequences in fibrinogen gamma-chain and tenascin C C-terminal domains critical for binding to integrin alpha vbeta 3. J Biol Chem, 2000; 275:16891–16898.
81.
CanfieldAE, SchorAM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci, 1995; 108(Pt 2): 797–809.
GohYY, et al.Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing. J Biol Chem, 2010; 285:32999–33009.
86.
ChongHC, et al.Angiopoietin-like 4 stimulates STAT3-mediated iNOS expression and enhances angiogenesis to accelerate wound healing in diabetic mice. Mol Ther, 2014; 22:1593–1604.
87.
LatijnhouwersM, et al.Human epidermal keratinocytes are a source of tenascin-C during wound healing. J Invest Dermatol, 1997; 108:776–783.
88.
Chiquet-EhrismannR, et al.Tenascin-C expression by fibroblasts is elevated in stressed collagen gels. J Cell Biol, 1994; 127(6 Pt 2): 2093–2101.
89.
ForsbergE, et al.Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Natl Acad Sci U S A, 1996; 93:6594–6599.
90.
SumiokaT, et al.Impaired cornea wound healing in a tenascin C-deficient mouse model. Lab Invest, 2013; 93:207–217.
91.
OkamuraN, et al.Deficiency of tenascin-C delays articular cartilage repair in mice. Osteoarthritis Cartilage, 2010; 18:839–848.
92.
TamaokiM, et al.Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol, 2005; 167:71–80.
93.
EggingD., et al.Wound healing in tenascin-X deficient mice suggests that tenascin-X is involved in matrix maturation rather than matrix deposition. Connect Tissue Res, 2007; 48:93–98.
94.
EggingD, et al.Interactions of human tenascin-X domains with dermal extracellular matrix molecules. Arch Dermatol Res, 2007; 298:389–396.
95.
AlcarazLB, et al.Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-beta. J Cell Biol, 2014; 205:409–428.
96.
TanioM, et al.Trivalent recognition unit of innate immunity system: crystal structure of trimeric human M-ficolin fibrinogen-like domain. J Biol Chem, 2007; 282:3889–3895.
97.
AhmedTA, DareEV, HinckeM. Fibrin: a versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev, 2008; 14:199–215.
98.
JanmeyPA, WinerJP, WeiselJW. Fibrin gels and their clinical and bioengineering applications. J R Soc Interface, 2009; 6:1–10.
99.
SeifertAW, et al.Skin regeneration in adult axolotls: a blueprint for scar-free healing in vertebrates. PLoS One, 2012; 7:e32875.
100.
VorotnikovaE, et al.Extracellular matrix-derived products modulate endothelial and progenitor cell migration and proliferation in vitro and stimulate regenerative healing in vivo. Matrix Biol, 2010; 29:690–700.
101.
WhitbyDJ, et al.Rapid epithelialisation of fetal wounds is associated with the early deposition of tenascin. J Cell Sci, 1991; 99(Pt 3):583–586.
102.
DalkowskiA, et al.Increased expression of tenascin C by keloids in vivo and in vitro. Br J Dermatol, 1999; 141:50–56.
103.
BartonWA, et al.Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nat Struct Mol Biol, 2006; 13:524–532.
104.
UgarovaTP, et al.Identification of a novel recognition sequence for integrin alphaM beta2 within the gamma-chain of fibrinogen. J Biol Chem, 1998; 273:22519–22527.
105.
PinedaAO, et al.Crystal structure of thrombin in complex with fibrinogen gamma’ peptide. Biophys Chem, 2007; 125:556–559.
